001     306595
005     20251128115928.0
024 7 _ |a 10.1126/scitranslmed.adu3313
|2 doi
024 7 _ |a pmid:41296826
|2 pmid
024 7 _ |a 1946-6234
|2 ISSN
024 7 _ |a 1946-6242
|2 ISSN
037 _ _ |a DKFZ-2025-02634
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Höckendorf, Ulrike
|0 0000-0002-8218-3343
|b 0
245 _ _ |a Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice.
260 _ _ |a Washington, DC
|c 2025
|b AAAS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764253236_4045023
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Acute myeloid leukemia (AML) is characterized by frequent relapse, which is driven by resistant leukemic stem or progenitor cells (LSCs). Here, we reported on a tumor-suppressive mechanism that can be harnessed to simultaneously clear LSCs and promote healthy hematopoiesis. Genetic deletion of the tumor necrosis factor (TNF) superfamily member lymphotoxin alpha (Lta) blocked cell death and accelerated leukemogenesis in murine AML models. Accordingly, exposure of leukemic cells to exogenous recombinant lymphotoxin alpha (LTα3) induced myeloid differentiation and, in part, cell death in AML progenitors. In syngeneic and patient-derived xenograft mouse models, exposure to recombinant LTα3 resulted in deep and durable remissions. LTα3 repressed leukemia by depleting tumor necrosis factor receptor (TNFR)-associated factor 2 (TRAF2) through activation of TNF receptors TNFR1 and TNFR2. In contrast with conventional therapies, LTα3 exerted only minimal toxicity on the healthy hematopoiesis but instead promoted hematopoietic progenitors. Leveraging this endogenous tumor-suppressive mechanism may decouple treatment efficacy on malignant cells from undesired bone marrow suppression.
536 _ _ |a 319H - Addenda (POF4-319H)
|0 G:(DE-HGF)POF4-319H
|c POF4-319H
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Lymphotoxin-alpha
|2 NLM Chemicals
650 _ 7 |a Receptors, Tumor Necrosis Factor, Type I
|2 NLM Chemicals
650 _ 7 |a Recombinant Proteins
|2 NLM Chemicals
650 _ 7 |a Receptors, Tumor Necrosis Factor, Type II
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: drug therapy
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: pathology
|2 MeSH
650 _ 2 |a Lymphotoxin-alpha: therapeutic use
|2 MeSH
650 _ 2 |a Lymphotoxin-alpha: pharmacology
|2 MeSH
650 _ 2 |a Hematopoiesis: drug effects
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cell Differentiation: drug effects
|2 MeSH
650 _ 2 |a Receptors, Tumor Necrosis Factor, Type I: metabolism
|2 MeSH
650 _ 2 |a Neoplastic Stem Cells: drug effects
|2 MeSH
650 _ 2 |a Neoplastic Stem Cells: pathology
|2 MeSH
650 _ 2 |a Neoplastic Stem Cells: metabolism
|2 MeSH
650 _ 2 |a Recombinant Proteins: pharmacology
|2 MeSH
650 _ 2 |a Recombinant Proteins: therapeutic use
|2 MeSH
650 _ 2 |a Receptors, Tumor Necrosis Factor, Type II: metabolism
|2 MeSH
700 1 _ |a Dutta, Sayantanee
|b 1
700 1 _ |a Kloos, Arnold
|0 0009-0001-4187-2513
|b 2
700 1 _ |a Runtsch, Marah
|0 0000-0002-9059-9269
|b 3
700 1 _ |a Zötsch, Carina
|0 0000-0002-9228-210X
|b 4
700 1 _ |a Vosberg, Sebastian
|b 5
700 1 _ |a Wang, Yongjie
|0 P:(DE-He78)54483eadd57bd53568e75b85a8711b96
|b 6
|u dkfz
700 1 _ |a Kienreich, Sophie
|0 0009-0005-9871-6983
|b 7
700 1 _ |a Flasch, Bettina
|0 0009-0005-0271-6832
|b 8
700 1 _ |a Malovan, Grazia
|b 9
700 1 _ |a Jäger, Vanessa
|0 0009-0003-7761-3606
|b 10
700 1 _ |a Stanzer, Stefanie
|0 0000-0002-5858-4067
|b 11
700 1 _ |a Prein, Stefanie
|b 12
700 1 _ |a Odinius, Timo O
|0 0000-0002-9722-4582
|b 13
700 1 _ |a Wagner, Celina V
|b 14
700 1 _ |a Buschhorn, Lars
|0 0000-0001-7162-816X
|b 15
700 1 _ |a Dill, Veronika
|0 0000-0002-4258-4986
|b 16
700 1 _ |a Perfler, Bianca
|0 0009-0007-2302-301X
|b 17
700 1 _ |a Haferlach, Torsten
|0 0000-0003-0196-2837
|b 18
700 1 _ |a Döhner, Konstanze
|b 19
700 1 _ |a Götze, Katharina S
|0 0000-0002-6276-8002
|b 20
700 1 _ |a Ruland, Jürgen
|0 0000-0002-8381-3597
|b 21
700 1 _ |a Bassermann, Florian
|0 0000-0003-4435-2609
|b 22
700 1 _ |a Wahida, Adam
|b 23
700 1 _ |a Heikenwälder, Mathias
|0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
|b 24
|u dkfz
700 1 _ |a Branca, Caterina
|b 25
700 1 _ |a Schmöllerl, Johannes
|0 0000-0002-8461-8881
|b 26
700 1 _ |a Zuber, Johannes
|0 0000-0001-8810-6835
|b 27
700 1 _ |a Burk, Ann-Cathrin
|b 28
700 1 _ |a Zeiser, Robert
|0 0000-0001-6565-3393
|b 29
700 1 _ |a Sill, Heinz
|0 0000-0003-0993-4371
|b 30
700 1 _ |a Jayavelu, Ashok Kumar
|0 P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af
|b 31
|u dkfz
700 1 _ |a Zebisch, Armin
|0 0000-0002-4861-7021
|b 32
700 1 _ |a Heuser, Michael
|b 33
700 1 _ |a Dengler, Michael A
|0 0000-0002-1693-1761
|b 34
700 1 _ |a Jost, Philipp J
|0 0000-0003-2454-0362
|b 35
773 _ _ |a 10.1126/scitranslmed.adu3313
|g Vol. 17, no. 826, p. eadu3313
|0 PERI:(DE-600)2518839-2
|n 826
|p eadu3313
|t Science translational medicine
|v 17
|y 2025
|x 1946-6234
909 C O |o oai:inrepo02.dkfz.de:306595
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)54483eadd57bd53568e75b85a8711b96
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 0000-0002-6276-8002
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 0000-0002-8381-3597
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 0000-0003-4435-2609
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-319H
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
920 1 _ |0 I:(DE-He78)A400-20160331
|k A400
|l KKE Pädiatrische Leukämie
|x 0
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 1
920 1 _ |0 I:(DE-He78)D440-20160331
|k D440
|l Chronische Entzündung und Krebs
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A400-20160331
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a I:(DE-He78)D440-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21